We can help you get approved medicine that isn't approved or available in your home country.. To learn more, fill out the form below.
OLAPARIB @ Maintenance Treatment of Recurrent Ovarian Cancer Lynparza is indicated for the adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy
OLAPARIB @ indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy
OLAPARIB @ indicated in patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
The information provided herein is not medical advice and is not intend to replace medical advice offered by a health care provider. Please consult your health care provider for advice.